

New York State Medication-Assisted Treatment Formulary Change

Effective October 1, 2021, the New York State Department of Health (NYSDOH) is requiring the implementation of the Medication-Assisted Treatment (MAT) formulary change for Managed Medicaid Members.

MVP Health Care® (MVP) originally communicated the formulary change to Members and Providers in November 2020, but the NYSDOH implementation was delayed in the interim. This formulary change will require that brand name Suboxone films be a preferred tier 1 medication. Generic Suboxone films (buprenorphine/naloxone) will be excluded. This formulary change affects the MVP Medicaid formulary only.

For prescriptions on or after October 1, 2021, the MVP Medicaid formulary will cover brand name Suboxone films (buprenorphine-naloxone films) without a prior authorization. These medications are subject to utilization management edits that MVP has in place to ensure appropriate utilization, including quantity limits. Generic Suboxone films (buprenorphine/naloxone) will be non-formulary, and coverage will be subject to prior authorization. If a patient's therapy requires them to be on generic buprenorphine/naloxone films, you may complete a prior authorization request form. Prior authorization requests must include clinical documentation to support the use of generic buprenorphine/naloxone films.

MVP continues to work with the NYSDOH for additional updates and guidance to understand and assess implications for our Members and our valued Providers.

To view all communications, visit mvphealthcare.com/FastFax

To receive future FastFax messages by email, contact your Professional Relations Representative

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-999-3920.

